Global oncology small molecule drugs market expected to reach $167,635 million by 2035
From GlobeNewswire: 2025-03-20 06:00:00
The global oncology small molecule drugs market is projected to reach USD 94,494 million in 2025, with a 5.9% CAGR until 2035. Targeted therapy is a cancer treatment that destroys cancer cells without harming normal cells. DNA alterations in cancer cells differ from regular cells, leading to fast growth. Monoclonal antibodies in immunotherapy enhance immune functions to fight cancer.
Understanding cancer cell changes drives targeted treatment drug development. These drugs are used alongside surgery, chemotherapy, hormone therapy, and radiation therapy. Major market players like AstraZeneca and Bristol-Myers Squibb lead in innovation. The market is expected to grow at a CAGR of 5.9%, reaching USD 167,635 million by 2035. North America dominates the market with a 34.6% share.
GSK’s strategic investments and drug development initiatives signal growth in the oncology small molecule drugs market. Pharmaceutical companies are expanding their cancer treatment portfolios. GSK’s positive outlook includes five medication approvals in 2025. AstraZeneca’s sales grew by 18% in the third quarter of 2024, with plans for research, development, and job creation in the US.
GSK’s Blenrep blood cancer drug showed promising results in combination with BorDex therapy. This combination reduced the risk of death compared to Darzalex therapy. The oncology small molecule drugs market is witnessing significant developments in blood cancer treatment. Pharmaceutical companies are investing heavily in new medications and initiatives to expand their market presence.
Fact.MR offers unbiased analysis of the global oncology small molecule market. The study provides insights on drug classes, indications, route of administration, and distribution channels across major regions. The market for coccidioidomycosis drugs is forecasted to grow at a CAGR of 4.9%, reaching USD 634.3 million by 2034. The global parenteral drug market is projected to reach USD 1,020.17 billion by 2034, with a 5.5% CAGR.
The alcohol breathalyzer and drug testing equipment market is expected to reach USD 37.26 billion by 2034, growing at a 7.3% CAGR. Sales of psoriasis drugs are forecasted to reach USD 27.57 billion by 2034. Fact.MR’s market research reports provide valuable insights for businesses looking to navigate dynamic market challenges and capitalize on emerging opportunities.
Read more at GlobeNewswire: Oncology Small Molecule Drugs Market is Expected to Expand